MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Authors

Srdan Verstovsek, The University of Texas MD Anderson Cancer Center
Stephen T Oh, Washington University School of Medicine in St. Louis
Et al

Journal

Future Oncology

Publication Date

4-1-2021

Volume

17

Issue

12

First Page

1449

Last Page

1458

Document Type

Open Access Publication

DOI

10.2217/fon-2020-1048

Rights and Permissions

Verstovsek S, Chen CC, Egyed M, Ellis M, Fox L, Goh YT, Gupta V, Harrison C, Kiladjian JJ, Lazaroiu MC, Mead A, McLornan D, McMullin MF, Oh ST, Perkins A, Platzbecker U, Scheid C, Vannucchi A, Yoon SS, Kowalski MM, Mesa RA. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol. 2021 Apr;17(12):1449-1458. doi: 10.2217/fon-2020-1048. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. For full bibliographic citation, please refer to the version available at www.futuremedicine.com.

Recommended Citation

Verstovsek, Srdan; Oh, Stephen T; and Et al, "MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic." Future Oncology. 17, 12. 1449 - 1458. (2021).
https://digitalcommons.wustl.edu/oa_4/419